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1. Introduction 
Transdermal medication conveyance frameworks are characterized as independent, discrete measurements frames 
which, when connected to in place skin, convey drug, through skin, at a controlled rate to systemic course. At present, most 
basic type of conveyance of medications is oral course. While this has outstanding focal point of simple organization, it 
additionally has critical disadvantages; in particular poor bioavailability because of first pass and propensity to create fast 
blood level spikes, prompting a requirement for high and/or successive dosing, which can be both expense restrictive and 
also awkward definitions on skin can be arranged into two classes as per target site of activity of containing medications. 
One has systemic activity after medication uptake from cutaneous micro vascular system, and different shows 
neighborhood impacts in skin. [1-5] 
Lornoxicam is a new non-steroidal anti-inflammatory agent (NSAIDs) of oxicam class with analgesic and anti-
pyretic properties. Lornoxicam used for the treatment of anti-inflammatory properties in a range of painful and 
inflammatory conditions, including Rheumatoid arthritis and postoperative pain. Lornoxicam is absorbed rapidly and 
almost completely from gastrointestinal tract. Top plasma focus is achieved inside 2.5 hrs. It has a generally short plasma 
half-life (3 to 5 hrs.). Bioavailability of Lornoxicam is 90-100 %. [6] 
The prime objectives were to develop Transdermal matrix patch that: 
1. To localize drug into systemic compartment devoid of being absorbed to avoid systemic side effects. 
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2. To control/modified release of drug at specific site and hence dose and dose frequency can be decrease thereby 
obtaining great therapeutic effectiveness. 
 
2. Materials and Method 
2.1 Materials [7-15] 
Lornoxicam was obtained from Ethicare pharma. pvt. Ltd. HPMC K-4, K-15, K-100 was obtained from Signet 
chem. Itd, Goa. Eudragit RS-100 was obtained from Signet chem. Itd. Mumbai. Ethyl cellulose, Chitosan, Polyethylene 
glycol-400, Tween 80, Methanol, Dichloromethane were obtained from Sulab (Pioneer sales). Baroda. 
2.2 Method of preparation 
2.2.1 Formulation of transdermal matrix patch by using solvent Casting Method: [16-17] 
The transdermal matrix patches will prepared by using solvent casting method. Required amount of plasticizer was 
added to polymer dispersion. Drug was dissolved to form aqueous solution with constant stirring for 30 minutes with 
adequate clarity and mixed in above dispersion. Solution was casted in a glass Petri dish (previously lubricated with 
glycerin) having diameter range of 7-8 cm and thickness 0.3-0.5 mm. Then it was dried at room temperature. It was 
approximately 24 hours to dry at room temperature; Dried TDDS was carefully removed from Petridis and was cut into size 
required for Evaluation.  
3. Evaluation of transdermal patch  
3.1. Physicochemical evaluation:
 
[18-25] 
3.1.1. Thickness:  
The thickness of drug prepared patch is measured by using a digital micrometer at different point of patch and 
determines average thickness and standard deviation for same to ensure thickness of prepared patch. 
3.1.2. Weight Uniformity: 
A specified area of patch is to be cut in different parts of patch and weigh in digital balance.  Average weight 
and standard deviation values are to be calculated from individual weights. 
3.1.3. Drug content Determination: 
An accurately weighed portion of film (above 100 mg) is dissolved in 100 mL of Phosphate buffer in which drug is 
soluble and then solution is shaken continuously for 24 hrs. in shaker incubator. Then whole solution is sonicated. After 
sonication and subsequent filtration, drug in solution is estimated spectrophotometrically.  
3.1.4. % Moisture Content: 
The prepared films are weighed individually and kept in a desiccators containing calcium chloride at room 
temperature for 24 hrs. Films are weighed again after a specified interval until they show a constant weight. % moisture 
content is calculated using following formula. 
𝑴𝒐𝒊𝒔𝒕𝒖𝒓𝒆 𝒄𝒐𝒏𝒕𝒆𝒏𝒕 =
𝑰𝒏𝒊𝒕𝒂𝒊𝒂𝒍 𝒘𝒕 − 𝑭𝒊𝒏𝒂𝒍 𝒘𝒕
𝑭𝒊𝒏𝒂𝒍 𝒘𝒕
∗ 𝟏𝟎𝟎 
3.1.5. % Moisture uptake: 
Weighed film sare kept in desiccators at room temperature for 24 h. These are then taken out and exposed to 84% 
relative humidity using saturated solution of Potassium chloride in a desiccator until a constant weight is achieved. % 
moisture uptake is calculated as given below. 
𝑴𝒐𝒊𝒔𝒕𝒖𝒓𝒆 𝑼𝒑𝒕𝒂𝒌𝒆 =
𝑭𝒊𝒏𝒂𝒍 𝒘𝒕.−𝑰𝒏𝒕𝒊𝒂𝒍 𝒘𝒕
𝑰𝒏𝒕𝒊𝒂𝒍 𝒘𝒕
∗ 𝟏𝟎𝟎 
3.1.6. Flatness: [40] 
Three longitudinal strips are to be cut from each film at different portion. Length of each strip was measured 
and variation in length because of   non-uniformity    in   flatness   was   measured   by   determining    percent 
constriction, with 0% constriction equivalent to 100% flatness. 
3.1.7. Folding Endurance:  
Folding endurance is determined by repeatedly folding film at same place until it break. Number of times films 
could be folded at same place without breaking is folding endurance value. 
3.1.8. Tensile Strength: 
The tensile strength was determined by using a modified pulley system. Strip of patch (2*2 cm
2
) was cut and set 
between these two clamps. Weight was gradually increased on pan, so as to increase pulling force till patch broke. Force 
required to break film was consider as a tensile strength (kg/cm
2
). 
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Tensile strength=F/a x b (1+L/l)  
                                            Where, F = force required to break;  
                                                          a=width of film; 
                                                          b = thickness of film;  
                                                          L = length of film; 
                                                          l =elongation of film at break point. 
3.1.9. Flux and Permeability coefficient:  
The flux (mg cm
-2
 hr
-1
) of Lornoxicam was calculated from slope of plot of cumulative amount of Lornoxicam 
permeated per cm
2
 of skin at steady state against time using linear regression analysis. Steady state permeability coefficient 
(Kp) of drug through rat epidermis was calculated by,  
Kp = J/C 
Where J = flux 
                                C = concentration of Lornoxicam in patch. 
3.1.10. In-vitro Permeation study  
An in-vitro permeation study can be carried out by using diffusion cell receptor compartment capacity of 12 ml. 
excised cellophane paper was mounted between donor and receptor compartment of diffusion cell. Formulated patches 
were placed over paraffin film. Receptor compartment of diffusion cell was filled with phosphate buffer pH 7.4. Whole 
assembly was fixed on a magnetic stirrer, and solution in receptor compartment was constantly and continuously stirred 
using magnetic beads at 50 rpm; temperature was maintained at 32 ± 0.5 °C.  
3.1.5.11. Kinetic Analysis of Release Data: [26-29] 
Table 1: Release Kinetic Mechanism 
Release Exponent ‘n’ Drug Transport Mechanism Rate as a function of Time 
0.5 Higuchi Matrix t
n-0.5
 
0.5<n<1.0 Non- Fickian Diffusion t
n-1
 
1.0 Zero Order Release special Case–II Transport Zero Order Release 
Higher release (n>1) Super Case–II Transport tn-1 
 
3.1.5.12. Solvent Residual Analysis 
Solvent Residual Analysis was done to determine organic solvent residual traces present in Transdermal Patch of 
used as Casting solvent. 
3.1.5.13. Skin irritation Study: 
Animals to be required 
1. Species/ Common Name: Wistar rats 
2. Weight: 150-200 grams 
3. Gender: Male 
Table 2: Protocol of skin irritation study 
Groups Route of drug 
administration 
No. of 
Animals Skin irritation studies 
Group-I: Control (Topical patch without drug) Topical 6 
Group-II: Standard Marketed conventional Diclofenac Patch Topical 6 
Group-III: Optimized Lornoxicam Patch loaded Topical Gel formulation Topical 6 
Procedure: 
Skin irritation and sensitization testing can be performed on healthy wister albino rats. rats were divided into 
three groups of six rats in each group. dorsal surface (4cm
2
) of rats were cleaned and remove hair from clean dorsal surface 
by shaving and clean surface by using rectified spirit and representative formulations can be applied over skin. patch is to 
be removed after 24 hrs and skin was observed and classified into 5 grades on basis of severity of skin injury. 
3.1.5.14. Stability study 
Stability studies will carried out for optimized patch formulation at Room Temperature  for 1 month. samples were 
withdrawn at 0, 10, 20, 30 days and evaluated for  Drug Content and in-vitro diffusion study. 
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4. Result and discussion 
4.1. Dose of Drug and Loading Dose Calculation: 
4.1.1. Dose of Drug: 
Dose of drug = (ORAL DOSE * ORAL BIOAVABILITY/ BODY SURFACE AREA) / 100 
Where oral dose of drug (Lornoxicam) =8 mg 
Oral bioavability = 90% 
Body surface area = 1.73 cm
2 
Dose of Drug = 4 mg  
4.1.2. Drug Loading Calculation: 
1. Average Patch Size= 21.2 cm
2  
2. Dose of Drug (Lornoxicam) = 4 mg 
    4 cm
2
 (2 cm X 2 cm) of Patch      = 4 mg of Drug (Lornoxicam). 
    So, 21.2 cm
2
 of petri plate size     =  (?) mg of Drug (Lornoxicam) require. 
                                                          =  4 X 21.2 / 4 
                                                          =  21.2 mg of Drug (Lornoxicam) in 21.2 cm
2
 of P.P. 
Table 4: Batch Design 
Code 
Drug 
(mg) 
HPMC k4M 
(mg) 
HPMC k15M 
(mg) 
HPMC k100M 
(mg) 
Eudragit RS 100 
(mg) 
PEG-400: 
Tween 80 
Solvent Total 
LXTMP 1 8 250 - - - 1:0.5 1:4 20ml 
LXTMP 2 8 300 - - - 1:0.5 1:4 20ml 
LXTMP 3 8 - 250 - - 1:0.5 1:4 20ml 
LXTMP 4 8 - 300 - - 1:0.5 1:4 20ml 
LXTMP 5 8 - - 250 - 1:0.5 1:4 20ml 
LXTMP 6 8 - - 300 - 1:0.5 1:4 20ml 
LXTMP 7 8 - - - 250 1:0.5 1:4 20ml 
LXTMP 8 8 - - - 300 1:0.5 1:4 20ml 
 
4.5. Characterization of Developed Transdermal patch: 
 
Table 5: Physico-chemical evaluation 
 
Batch 
Code 
Parameter(n = 3) 
Thickness (mm) ± 
S.D 
Weight uniformity 
(gm) ± S.D. 
Drug content 
(%)± S.D. 
Folding Endurance 
±S.D. 
Flatness (%) 
±S.D. 
LXTMP 1 0.27±0.06 0.246±0.0045 93.3±1.93 65.00±4.58 90±2.52 
LXTMP 2 0.26±0.04 0.294±0.0021 95.4±2.08 68.33±6.03 96±1.53 
LXTMP 3 0.29±0.03 0.252±0.0020 91.2±3.39 78.33±2.52 91±4.51 
LXTMP 4 0.32±0.03 0.299±0.0026 93.0±2.57 72.67±2.52 93±1.53 
LXTMP 5 0.34±0.04 0.254±0.0010 90.0±4.70 70.33±5.03 94±4.04 
LXTMP 6 0.33±0.03 0.302±0.0030 92.4±1.87 70.67±3.06 89±4.16 
LXTMP 7 0.37±0.05 0.242±0.0065 94.2±1.00 73.33±9.02 92±2.52 
LXTMP 8 0.40±0.06 0.295±0.0055 92.4±1.91 70.00±2.00 91±3.51 
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Figure 1: Physicochemical evaluation of LXTMP1-LXTMP8 (Thickness, weight uniformity) 
 
Figure 2: Physicochemical evaluation of LXTMP1-LXTMP8 (Drug content, Folding Endurance, Flatness) 
 
Table 6: Tensile Strength, % Swelling Index, Moisture Uptake and Moisture Content 
 
Batch 
Code 
Parameter(n = 3) 
Tensile Strength (Kg/cm
2
) ± 
S.D. 
Swelling Index % ± 
S.D. 
%Moisture Content ± 
S.D. 
% Moisture Uptake 
±S.D. 
LXTMP 1 2.3±0.153 28.32±1.84 5.8±0.55 10.9±0.31 
LXTMP 2 2.5±0.252 30.53±2.23 6.7±0.15 12.2±1.99 
LXTMP 3 2.7±0.300 14.38±3.15 6.9±0.35 10.7±2.00 
LXTMP 4 3.1±0.351 21.05±3.59 7.2±0.31 11.6±1.71 
LXTMP 5 3.4±0.058 25.48±2.98 7.9±0.21 9.0±0.56 
LXTMP 6 3.6±0.208 29.38±1.95 8.3±0.25 9.5±1.25 
LXTMP 7 4.2±0.252 12.42±2.18 5.6±0.21 8.0±1.72 
LXTMP 8 4.3±0.200 23.90±3.56 5.2±0.35 6.3±0.69 
 
Physicochemical evaluation of LXTMP1-LXTMP8(Thickness,weight 
uniformity)
Flatness
Folding Endurance
Drug content
Physicochemical evaluation of LXTMP1-LXTMP8(Drug content,Folding 
Endurance, Flatness)
Weight uniformity
Thickness
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4.5.3. In-vitro permeation study: 
 
Figure 3: In-vitro permeation study  
Table 7: In-vitro permeation study  
Time 
(Hrs) 
% Cumulative drug release (n=3) 
LXTMP 
1± S.D 
LXTMP 
2± S.D 
LXTMP 
3± S.D 
LXTMP 
4± S.D 
LXTMP 
5± S.D 
LXTMP 
6± S.D 
LXTMP 
7± S.D 
LXTMP 
8± S.D 
0 0 0 0 0 0 0 0 0 
1 6.47±1.20 6.06±1.25 5.66±1.63 5.42±0.54 4.85±0.43 4.69±0.45 4.69±0.91 4.77±0.65 
2 9.43±0.98 9.16±2.34 8.56±0.87 7.73±0.35 7.76±1.12 7.67±0.21 7.67±1.02 6.70±2.12 
3 15.03±1.23 13.36±1.54 11.66±1.24 10.76±1.24 10.80±2.01 10.54±1.24 10.54±0.64 9.98±0.90 
4 18.60±1.85 18.57±1.24 15.93±1.14 15.77±0.85 13.15±1.32 13.11±2.01 13.11±0.37 14.13±0.56 
5 22.37±1.94 23.25±2.05 18.87±0.95 17.74±1.12 18.95±1.04 17.61±1.52 17.61±1.09 17.92±0.74 
6 27.16±1.24 25.86±0.84 22.28±1.24 20.42±0.97 22.72±0.62 24.19±1.92 20.15±0.92 21.29±0.83 
7 32.21±0.68 31.21±0.94 27.16±2.14 25.82±0.52 25.32±0.78 25.31±0.64 23.92±1.23 25.56±0.25 
8 38.34±1.25 37.28±0.24 32.88±1.52 30.73±1.34 28.34±0.24 28.32±0.72 28.06±0.64 28.77±1.63 
9 44.00±2.18 42.87±0.67 38.54±0.64 33.90±2.12 33.56±1.39 31.21±1.02 30.55±0.95 31.87±1.02 
10 50.74±1.40 48.73±0.84 43.11±0.38 39.60±1.56 39.49±2.14 36.77±0.64 35.86±0.46 35.16±0.56 
11 56.20±1.34 53.25±1.07 48.84±0.74 46.00±2.04 43.71±1.14 41.68±0.53 43.15±1.52 41.88±0.95 
12 61.86±0.87 58.71±1.13 54.83±1.04 51.12±1.87 49.47±1.37 47.14±1.34 50.22±2.08 46.97±1.59 
 
%Moisture Content,%Moisture Uptake,%Swelling Index
swelling index
Moisture Uptake
Moisture content
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Table 8: Flux and permeability co-efficient 
 
Time (hrs) 
Batch F1 
Flux J (mg/cm2/hr) 
 
Permeability 
co-efficient (kP)  
0 0.000 0 
1 0.793 0.037393 
2 0.773 0.03646 
3 0.014 0.000654 
4 0.006 0.00028 
5 0.007 0.000354 
6 0.010 0.000472 
7 0.010 0.000472 
8 0.013 0.00059 
9 0.174 0.008203 
10 0.217 0.010254 
11 0.130 0.006153 
12 0.083 0.003931 
Table 9: Kinetic analysis of release data 
Model Zero-Order First-Order Hixson-Crowell Korsmeyer-Peppas Higuchi 
R
2
 value 0.992 0.874 0.965 0.751 0.945 
Slope 5.415 0.113 0.568 0.901 0.042 
Intercept -0.321 0.675 1.784 -0.782 0.790 
 
4.5.6 Solvent Residual: 
 
 
 
 
 
CDR1
CDR3
CDR5
CDR7
%
C
D
R
TIME
In-Vitro Diffusion of LXTMP 2,4,6,8
CDR2
CDR4
CDR6
CDR8
International Journal of Advances in Pharmaceutics 5 (2) 2016                                                                                   37 
 
 
4.5.7. Skin irritation study 
  
Figure 4: Skin irritation study 
4.5.8. Stability Study 
Table 11: Stability Study 
Temperature/ 
Humidity condition 
Time (Days) 
Drug Content (%) In-vitro drug release (%) 
Initial± S.D Final± S.D Initial± S.D Final± S.D 
 0 93.3±1.12 93.5±0.95 61.8±1.56 60.3±1.02 
10 93.3±0.85 93.4±0.112 61.8±2.03 60.5±2.31 
Room Temperature 20 93.3±0.94 93.3±0.34 61.8±0.78 61.5±1.16 
30 93.3±1.24 93.1±0.84 61.8±1.26 61.7±0.94 
 
5. Summary and conclusion 
 Transdermal therapeutic systems are defined as self-contained, discrete dosage forms which, when 
applied to intact skin, deliver drug(s), through skin, at a controlled rate to systemic circulation. By development of 
transdermal matrix patch of Lornoxicam using HPMC and Eudragit RS-100  as release controlling polymers and 
Dichloromethane: Methanol (1:4) as solvent, increases permeability and bioavailability of Lornoxicam and increase 
patient compliance. All formulations showed acceptable physiochemical characteristics i.e. appearance, thickness, folding 
endurance, moisture content. From identification tests such as Ultra violet visible spectroscopy, Infrared spectroscopic 
study, melting point, partition co-efficient it was conclude that drug sample is Lornoxicam with acceptable purity grade. 
Partition coefficient Value shows that Lornoxicam possess sufficient lipophilicity. A low concentration of Plasticizer gives 
a rigid and brittle polymeric film. So plasticizer is required to improve mechanical property.  HPMC and Eudragit RS-100 
both are hydrophilic polymers in nature. As molecular weight of polymer increases viscosity also increase. Elasticity and 
elongation is more in HPMC higher percentage than Eudragit. In-vitro permeation study shows that formulation of 
LXTMP 1 batch with HPMC K- 4 M shows more sustained release of drug during 12 hrs study 
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